Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STR-324 in Healthy Subjects
NCT03430232Phase 1Completed
- Sponsor
- Stragen
- Start
- Feb 2018
- Primary completion
- Nov 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STR-324 in pain (5 arms), sponsored by Stragen. Primary endpoint: Safety and tolerability. Started Feb 2018; status: completed.
02
Drugs
STR-324
03
Conditions
pain
Beyond the preview
Go deeper on NCT03430232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430232.